度拉糖肽联合二甲双胍对肥胖型2型糖尿病的治疗效果及对血糖变异性体质量的影响  

Effects of Dulaglutide combined with Metformin on obesity-related type 2 diabetes mellitus and its influ-ence on blood glucose variability and body mass

作　　者：顾跃 章卫健 周莉 钱海娟 

机构地区：[1]平湖市第二人民医院内分泌科,浙江平湖314201 [2]平湖市第二人民医院体检中心,浙江平湖314201

出　　处：《中国药物与临床》2024年第9期569-573,共5页Chinese Remedies & Clinics

基　　金：浙江省平湖市科技计划项目(2023-44)。

摘　　要：目的探讨度拉糖肽联合二甲双胍治疗肥胖型2型糖尿病(T2DM)的效果及对血糖变异性(GV)、体质量的影响。方法选取2023年3月至10月于浙江省平湖市第二人民医院被诊断为肥胖型T2DM的患者100例,按照随机数字表法将其分为观察组(度拉糖肽联合二甲双胍,50例)和对照组(二甲双胍治疗,50例)2组。对比2组疗效、糖脂代谢指标水平、GV、身体指标情况。结果治疗后,观察组的临床总有效率高于对照组(94%与82%,P<0.05);观察组血清糖脂代谢水平与对照组比较差异具有统计学意义[总胆固醇(4.12±0.41)与(4.87±0.67)mmol/L,三酰甘油(2.51±0.36)与(3.12±0.40)mmol/L,高密度脂蛋白胆固醇(1.39±0.31)与(1.05±0.27)mmol/L,低密度脂蛋白胆固醇(2.05±0.26)与(2.96±0.43)mmol/L,空腹血糖(6.10±0.72)与(8.24±1.12)mmol/L,空腹胰岛素(5.02±0.51)与(6.78±0.67)μU/ml](P<0.05)。结论肥胖型T2DM应用度拉糖肽与二甲双胍的联合治疗方案的临床效果良好,可有效改善糖脂代谢情况、GV、体质量。Objective To investigate the effect of Dulaglutide combined with Metformin on obesity-related type 2 diabetes mellitus(T2DM)and its influence on blood glucose variability(GV)and body mass.Methods A total of 100 patients diagnosed with obesity-related T2DM were selected at the Health Examination Center of Pinghu Second People′s Hospital between March 2023 and October 2023,and were divided into an observation group(dulaglutide combined with metformin,n=50)and control group(treated with metformin,n=50)according to random sampling method and random sequence.The therapeutic effects,levels of glucose and lipid metabolism indicators,GV and physical indicators were compared between the two groups.Results After treatment,the total clinical effective rate of the observation group was significantly higher than that of the control group(94%vs 82%,P<0.05);There was a significant difference in serum glucose and lipid metabolism levels between the observation group and the control group[TC(4.12±0.41)vs(4.87±0.67)mmol/L,TG(2.51±0.36)vs(3.12±0.40)mmol/L,HDL-C(1.39±0.31)vs(1.05±0.27)mmol/L,LDL-C(2.05±0.26)vs(2.96±0.43)mmol/L,FPG(6.10±0.72)vs(8.24±1.12)mmol/L,FINS(5.02±0.51)vs(6.78±0.67)mmol/L]μU/ml(P<0.05);The mean amplitude of glycemic excursions(MAGE)and standard deviation(SD)of the observation group were lower than those of the control group[(2.65±0.38)vs(3.14±0.31)mmol/L,(1.45±0.52)vs(2.17±0.41)mmol/L](P<0.05);The body mass,BMI,and visceral fat thickness of the observation group were lower than those of the control group[(68.16±3.48)vs(71.16±3.46)kg,(24.57±0.89)vs(26.18±0.55)kg/m2,(25.68±1.32)vs(27.02±0.31)mm](P<0.05).Conclusion The treatment of dulaglutide combined with metformin has a good therapeutic effect on obesity-related T2DM,which can effectively improve glucose and lipid metabolism,GV,and body mass.

关 键 词：二甲双胍 度拉糖肽 糖尿病 2型 血糖 人体质量指数 

分 类 号：R587.1[医药卫生—内分泌]